Insurance Change Protocols for Active Infusion Patients
An insurance change protocol must keep treatment on track for active infusion patients and ensure that the practice gets paid. A new plan resets the terms behind every infusion. The practice needs a standing workflow that catches the change, rebuilds authorization, and checks payment before one missed transition becomes a run of unpaid claims.
Why an insurance change mid-treatment is a revenue cycle emergency, not a scheduling inconvenience
A patient who has been stable on a biologic for six months arrives for the next infusion and mentions a job change. The appointment is still on the calendar, but the financial basis for it may have disappeared. Prior authorization, formulary status, network participation, and the reimbursement pathway all need fresh confirmation. These requirements change in parallel, so the practice must address them all to clear the treatment for payment.
That matters because infusion practices commit money before a claim is paid. Under buy-and-bill, the practice holds the drug acquisition cost from the moment it is ordered. If the new plan denies payment after administration, the drug has been consumed and that cost remains unrecovered without a successful appeal. This is not the same exposure as a routine visit that needs a new eligibility check.
Recurring-therapy patients on biologics including infliximab, rituximab, and natalizumab are especially exposed. Their authorization clocks were already running under the old plan, but a change of insurance resets the clock regardless of the renewal date. Infusion Access Foundation's 2026 open enrollment guide illustrates how formulary placement, prior authorization requirements, and network participation vary across plan types. The patient’s treatment may be unchanged while every condition for paying for it has moved.
What the 90-day continuity-of-care commitment covers — and what it does not
A temporary protection now exists for some of these transitions. Effective January 1, 2026, participating health plans honor existing prior authorizations for “benefit-equivalent in-network services” for 90 days when a patient changes insurance during treatment. AHIP and BCBSA announced the voluntary initiative in June 2025. AHIP's January 2026 update says that health plans that serve nearly 270 million Americans are taking part.
The commitment covers commercial, Medicare Advantage, and Medicaid managed care plans in line with the rules that apply to them. It is voluntary, and self-funded ERISA plans are outside its reach. The service conditions matter just as much as participation. If the infusion center is out-of-network or the new plan does not cover the biologic on its formulary, the bridge may not apply.
Even when the service qualifies, the bridge does not activate itself. Staff must tell the new payer, keep a record of the old plan’s approval, and start re-authorization before the window closes. Billing whichever plan the patient presents is not enough to capture this protection. Without the notification and documentation, the practice cannot assume the new payer will honor the old approval.
State requirements add another layer, with some states codifying 90-day transition protections subject to additional conditions. Those requirements vary and do not extend state insurance authority to self-funded ERISA plans. The practice must therefore confirm that this patient’s plan and service qualify for the bridge and that it has taken the required steps.
How insurance changes reach the practice — and why passive detection fails
The first place to audit is the gap between intake verification and recurring appointments. A practice may correctly check coverage at intake, record an authorization, and then keep booking appointments based on that record. In the meantime, a patient who gets an infusion every eight weeks may change insurance in week three. Without another check before the next infusion, staff may miss the change because they still rely on the original record.
Patients may not connect a job change, a spouse’s open enrollment choice, or aging off a parent’s plan with the need to contact the infusion center immediately. Passive workflows therefore discover changes through an eligibility error at claim submission, a coverage-terminated code on a remittance, or a call about an unexpected bill. All are late signals. By then, one or more infusions may already have been administered without valid authorization under the new plan.
Active detection requires more than confirming that the patient has coverage. Eligibility verification must run at every appointment and compare the current plan with the plan on file. A mismatch is the trigger for the insurance-change workflow. Outbound contact before each infusion cycle provides a second detection layer by asking directly about coverage changes.
The authorization reset — what must be re-verified before the next infusion
Formulary status comes first because the biologic must be covered under the new plan’s formulary. The drug may be on a different tier, need step therapy, or be excluded from coverage. An authorization request cannot substitute for understanding that coverage boundary. Network participation comes next because the infusion center must be an acceptable site of care under the new plan. If the center is out-of-network, the practice faces a reimbursement problem and the patient faces a site-of-care decision before treatment.
With those conditions established, staff must review the new payer’s medical necessity criteria for the biologic and diagnosis. Clinical documentation that satisfied the old plan may not satisfy the new one. Step-therapy requirements need a separate check because the new payer may require prior failure on another agent, even when the patient has been stable for years. Treatment stability alone does not establish that the new plan’s criteria have been met.
Staff next check the authorization type, which submission channel to use, and when authorization is needed. AHIP's January 2026 update states that nearly half of prior authorization requests are submitted by fax or phone. If the new payer requires electronic submission, a fax-based workflow may leave the request unreceived or unprocessed. The new authorization interval must also replace the old renewal schedule, such as when a 12-month approval becomes a 6-month cycle. Staff also need to check the deductible, coinsurance, and out-of-pocket maximum again through benefits verification so they can explain costs to patients and collect what they owe.
How the 90-day bridge interacts with re-authorization timing — and where the clock runs out
The bridge is a deadline. For a patient on an eight-week infusion cycle, it may protect only one treatment cycle before another approval is needed. If detection happens at the next appointment rather than when coverage changes, part of the window is already gone. If re-authorization starts at day 60 or later, the next infusion may fall in a gap between approvals.
Payer turnaround does not remove that risk. CMS-0057-F requires impacted payers to decide standard requests within 7 calendar days and urgent requests within 72 hours. Those timelines begin only when the submission is complete, and an incomplete submission restarts the clock. Time lost before submission therefore matters as much as time spent waiting for the payer.
Re-authorization submission should begin within the first two weeks of detecting the change, leaving room for review, a potential peer-to-peer, and an appeal if needed. Each file must show when staff detected the change, when the bridge started, and when the request was submitted so staff know how much time they have. A step-therapy denial requires immediate action. If approval is still missing at expiration, the practice faces a blunt choice between delaying treatment and administering without authorization. The purpose of the bridge is to avoid reaching that choice without time left to resolve it.
Denial patterns that follow insurance transitions and how to distinguish them from ordinary denials
Transition-related denials need their own category because their root cause is a mismatch in coverage terms. A coverage-terminated or patient-not-eligible denial can mean the claim went to the old plan after the new plan took effect. That points back to detection failure. A no-authorization-on-file denial from the new plan instead points to a gap between treatment and re-authorization. Sending both through a routine correction workflow hides the difference.
A non-covered-service or formulary-exclusion denial calls for formulary exception or site-of-care reconsideration. For a step-therapy denial, staff need to send clinical documentation of the patient’s past treatment because rebilling the same claim will not address it. An out-of-network denial points to a missed network check and may require a gap exception or single-case agreement.
CARC and RARC codes on the 835 remittance help distinguish coverage, authorization, formulary, and network issues. But each payer has its own coding, so a Blues plan and a commercial managed care plan may use different codes for the same problem. Grouping denials by CARC alone can hide their transition origin. A separate transition-denial category, tagged to the patient’s insurance change date, preserves that connection. It also lets the practice measure how many denials each transition generates and whether the protocol is reducing that number.
AR exposure from insurance transitions and how it compounds when transitions go unmanaged
A missed insurance change can create several unpaid claims before anyone resolves the first. For a patient on an eight-week cycle, two or three infusions may occur before the payer issues the first denial. Each infusion without valid authorization under the new plan adds a separate claim at risk. With high-cost buy-and-bill drugs, the exposure includes money already spent on medication that cannot be recovered from the patient’s completed treatment.
As those claims age, recovery becomes harder. Once claims pass 90 days, the chance of collecting drops to roughly 50%, and payers are more likely to treat them as non-collectible as they near the 120-day mark. Payer-specific timely filing limits may then prevent refiling altogether. Resolving the coverage mismatch quickly protects more than the first denied claim.
Partial payment can conceal another loss if the claim is paid under the wrong plan’s fee schedule. Line-level reconciliation against the new plan’s contracted rates is needed to catch that underpayment before it becomes a write-off. A cluster of denials from the same payer and date-of-service range in the 60-to-90-day bucket, especially with eligibility or authorization codes, should trigger review against insurance change dates. Staff need to follow up right away on high-dollar infusion claims that have denial and authorization flags. That priority keeps transition failures from drifting into the 90-plus-day range.
Building a standing protocol — the workflow touchpoints that catch transitions before they become denials
The first touchpoint belongs in scheduling and appointment confirmation, 4–7 days before each infusion. Outbound contact should ask whether insurance has changed since the last visit, making the question a routine part of preparation. A reported change triggers full re-verification immediately. It should not wait for the patient to arrive, when the remaining time to protect treatment and payment is shortest.
The second touchpoint is eligibility verification before every infusion. Staff must compare the result with the plan on file, looking for a different payer ID, group number, or effective date. Any mismatch triggers the same workflow as a patient-reported change.
The third touchpoint is re-verification and bridge notification within 48 hours of detection. Staff check the formulary status, network participation, medical necessity criteria, and step-therapy requirements that apply under the new plan. They also notify the payer of the existing authorization and supply the old plan’s approval documentation where the bridge applies. Re-authorization submission begins immediately. The review must account for plan type and any additional state-regulated transition requirements.
The fourth touchpoint is authorization tracking. The patient file must carry the detection date, bridge start and expiration dates, re-authorization submission date, new approval date, and new authorization expiration date. The new plan’s interval replaces the old renewal schedule. Automated reminders should fire at least 30 days before authorization expiration, while there is still time to act.
The fifth touchpoint is the first remittance from the new plan. Staff review it line by line against that plan’s contracted rates. Coverage, authorization, or network adjustment codes are signals of a possible protocol failure and require immediate escalation.
Execution requires both tracking and people responsible for the work. Software can track eligibility and authorization timelines, while operators submit requests, notify the payer, and follow up on denials. Neither replaces the other. The protocol is complete only when the change has been detected, the new coverage conditions have been met, and the first payment has been checked.
